血清ProGRP和NSE在晚期非小细胞肺癌治疗耐药中的价值  

Value of Serum ProGRP and NSE in Drug Resistance of Advanced Non-small Cell Lung Cancer

作　　者：马晓平 闫红娟[2] 徐丹 巩平[1] MA Xiao-ping;YAN Hong-juan;XYU Dan;GONG Ping(Department of Oncology,the First Affiliated Hospital of Shihezi University,Xinjiang Shihezi,832008;Department of Stomatology,the First Affiliated Hospital of Shihezi University,Xinjiang Shihezi,832008;The Third People's Hospital of Zhenjiang City,Jiangsu Zhenjiang,212000)

机构地区：[1]石河子大学第一附属医院肿瘤内科,新疆石河子832008 [2]石河子大学第一附属医院口腔科,新疆石河子832008 [3]镇江市第三人民医院,江苏镇江212000

出　　处：《农垦医学》2023年第3期198-203,共6页Journal of Nongken Medicine

基　　金：国家自然科学基金(81560381)。

摘　　要：目的:检测晚期非小细胞肺癌(Non-Small Cell Lung Cancer,NSCLC)治疗耐药前后血清胃泌素释放肽前体(Gastrin Releasing Peptide Precursor,ProGRP)和神经元特异性烯醇化酶(Neuron-Specific Enolase,NSE)水平,分析其与患者治疗方案之间的相关性,初步探讨其在耐药后的临床意义。方法:收集75例晚期NSCLC患者治疗耐药前后清晨空腹外周静脉血液标本,采用电化学发光免疫分析法检测血清PorGRP和NSE水平。结果:75例晚期NSCLC患者,耐药后血清ProGRP和NSE平均水平均高于耐药前血清ProGRP和NSE平均水平,差异有统计学意义(P<0.001),血清ProGRP和NSE两者水平在NSCLC治疗耐药后具有相关性(P<0.001);晚期NSCLC靶向治疗耐药后血清ProGRP和NSE水平明显高于单纯化疗耐药后血清ProGRP和NSE水平,差异有统计学意义(P值均小于0.05);75例晚期NSCLC患者,治疗耐药后23例进行二次病理学检查,其中3例转化为小细胞肺癌(Small Cell Lung Cancer,SCLC),其血清ProGRP和NSE水平均呈高表达状态,均为腺癌、表皮生长因子受体(Epidermal Growth Factor Receptor,EGFR)阳性患者,比例约13.04%(3/23)。结论:血清ProGRP和NSE水平与晚期NSCLC治疗耐药具有相关性,通过二者的检测有助于判断晚期NSCLC药物治疗预后,为临床治疗NSCLC提供新思路。Objective:To check the serum gastrin releasing peptide precursor(ProGRP)and the neuron-specific enolase(NSE)levels before and after the drug resistance of Non-small cell Lung cancer(NSCLC)treatment and analyse their relations with the patients'treatment.To investigate the clinical significance after drug resistance.Methods:Blood samples of 75 terminal patients of NSCLC from peripheral veins on an empty stomach in the morning before and after the drug resistance of non-small-cell Lung Carcinoma treatment were collected.Serum ProGRP and NSE levels were determined by electrochemiluminescence immunoassay.Results:In 75 terminal patients of NSCLC,Serum ProGRP and NSE average levels after the drug resistance of NSCLC treatment were higher than those of before the drug resistance of non-small-cell Lung Carcinoma treatment.And the differences were statistically significant(P<0.001).There is an association between Serum ProGRP level and the NSE level after the drug resistance of non-small-cell Lung Carcinoma treatment(P<0.001).Serum ProGRP and NSE levels of targeted therapy were higher than those of simple chemotherapy after the drug resistance.And the differences were statistically significant(P<0.05).Among 75 terminal patients of NSCLC,23 patients were examined pathologically again after the drug resistance.3 patients were transformed into small-cell Lung Carcinoma(SCLC),and their serum ProGRP and NSE levels were in hyper expressive state,adenocarcinoma and EGFR positive,accounting for 13.04%(3/23).Conclusions:Serum ProGRP and NSE levels were associated with the drug resistance of treatment in advanced non-small cell lung cancer.It is helpful to judge the prognosis of advanced non-small cell lung cancer(NSCLC)by examining the Serum ProGRP and NSE levels and provide a new idea for clinical treatment of NSCLC.

关 键 词：非小细胞肺癌 胃泌素释放肽前体 神经元特异性烯醇化酶 耐药 

分 类 号：R734.2[医药卫生—肿瘤]